Sign In
Buy MYL
$15.86
+0 (+0%)
At Close: May 27, 2022
Mylan, Inc. (MYL) CEO Heather Bresch on Q2 2020 Results - Earnings Call Transcript
04:52am, Friday, 07'th Aug 2020
Mylan, Inc. (NASDAQ:MYL) Q2 2020 Results Conference Call August 06, 2020 10:30 AM ET Company Participants Melissa Trombetta - Head of Global Investor Relations Robert Coury - Chairman & Non-Execut
Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
05:24pm, Thursday, 06'th Aug 2020
Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.
Mylan (MYL) Surpasses Q2 Earnings and Revenue Estimates
11:45am, Thursday, 06'th Aug 2020
Mylan (MYL) delivered earnings and revenue surprises of 16.84% and 1.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Mylan swings to profit as sales fall slightly short of estimates
10:56am, Thursday, 06'th Aug 2020
Mylan N.V. said Thursday it had net income of $39.4 million, or 8 cents a share, in the second quarter, after a loss of $168.5 million, or 33 cents a share, in the year-earlier period. The company sa
Mylan tightens revenue estimates on COVID-19 pressure; shares fall
10:46am, Thursday, 06'th Aug 2020
Generic drugmakers like Mylan benefited in the first quarter from customers stocking up on over-the-counter medicines ahead of the lockdowns imposed to curb the spread of the virus. The stockpiling,
Mylan posts quarterly profit compared to year-earlier loss
10:41am, Thursday, 06'th Aug 2020Mylan Reports Strong Second Quarter and First Half 2020 Results and Updates 2020 Guidance
10:30am, Thursday, 06'th Aug 2020
Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and six months ended June 30, 2020.
Delaware Enhanced Global Dividend and Income Fund Announces Distributions
08:59pm, Tuesday, 04'th Aug 2020
Today, Delaware Enhanced Global Dividend and Income Fund (the "Fund"), a New York Stock Exchange–listed closed-end fund trading under the symbol "DEX," declares a monthly distribution of $0.0513 per
NEW YORK, NY / ACCESSWIRE / August 2, 2020 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.
Mylan (MYL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04:33pm, Thursday, 30'th Jul 2020
Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mylan (MYL) to Report Q2 Earnings: Is a Beat in the Cards?
03:00pm, Thursday, 30'th Jul 2020
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.
Why Mylan (MYL) Could Beat Earnings Estimates Again
04:10pm, Wednesday, 29'th Jul 2020
Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer Stock Jumps on Earnings Beat and Vaccine Progress
12:59pm, Tuesday, 28'th Jul 2020
The update comes as Pfizer emerges as among the leaders in the race to develop the first Covid-19 vaccine. On Monday night, the company announced that its program had hit a new milestone, saying it h
Pfizer Surges On Coronavirus Vaccine Supply Deals — But Is PFE Stock A Buy?
02:00pm, Monday, 27'th Jul 2020
Pfizer stock briefly broke out from a cup base as the Street intently watches its coronavirus vaccine efforts with BioNTech. But is the pharmaceutical company's stock a buy right now?
Pfizer Reports Earnings Tomorrow. Here’s What to Expect.
02:00pm, Monday, 27'th Jul 2020
The update comes at a moment of peril and promise for the company. Pfizer, with its partner BioNTech are developing what some analysts have called the most promising of the first batch of Covid-19 vac
